Overall, our results suggest methylation alteration at this SHANK1 CpG island as a biomarker for risk and diagnosis of CLL, and also in the personalized quantification of tumor aggressiveness. This evidence concerns the gene SHANK1 and B-cell chronic lymphocytic leukemia.